JGC
PTGX icon

J. Goldman & Co’s Protagonist Therapeutics PTGX Stock Holding History

J. Goldman & Co’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-40,700
Closed -$3.55M – 842
2025
Q4 		$3.55M Buy
+40,700
New +$3.33M 0.09% 242
2025
Q2 		– Sell
-42,600
Closed -$2.06M – 602
2025
Q1 		$2.06M Buy
+42,600
New +$1.79M 0.05% 290
2023
Q3 		– Sell
-54,000
Closed -$1.49M – 462
2023
Q2 		$1.49M Buy
+54,000
New +$1.35M 0.05% 229

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

J. Goldman & Co's PTGX Position: Q1 2026 in Review

J. Goldman & Co reduced its Protagonist Therapeutics (PTGX) stake by 79% in Q1 2026, selling an estimated $3.24M and leaving 9,714 shares worth $1.02M. The position accounts for 0.03% of the portfolio, ranked #414.

J. Goldman & Co first reported a position in PTGX in Q2 2020 and has held it in 12 quarters since. The position peaked at $4.46M in Q4 2021. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • J. Goldman & Co held 9,714 shares of Protagonist Therapeutics worth $1.02M as of Q1 2026.
  • J. Goldman & Co sold 36,611 Protagonist Therapeutics shares in Q1 2026, an estimated $3.24M.
  • Protagonist Therapeutics made up 0.03% of J. Goldman & Co's portfolio in Q1 2026, its #414 holding.
  • J. Goldman & Co first reported a position in Protagonist Therapeutics in Q2 2020 and has held it in 12 quarters since.
  • J. Goldman & Co's Protagonist Therapeutics position peaked at $4.46M in Q4 2021.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.